Robert Z Orlowski, MD, PhD

Robert Z Orlowski, MD, PhD, professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center, on the importance of the SWOG S0777 trial. Data from the trial shows induction therapy with a triplet of bortezomib, lenalidomide, and dexamethasone improved both progression-free survival and overall survival over lenalidomide and dexamethasone alone in patients with untreated multiple myeloma.

Orlowski says oncologists have been using a combination of bortezomib, lenalidomide, and dexamethasone for years as the

frontline treatment, despite phase III trial data was not present. He says this is important for oncologists because the triplet now joins the Category 1 recommendation level from the National Comprehensive Cancer Network.

Videos

Data from the trial shows induction therapy with a triplet of bortezomib, lenalidomide, and dexamethasone improved both progression-free survival and overall survival over lenalidomide and dexamethasone alone in patients with untreated multiple myeloma.

Robert Z Orlowski, MD, PhD | Authors

Articles

Dr. Robert Z Orlowski on the Importance of the Phase III SWOG S0777 Trial